Our novel, non-addictive lead asset is designed to avoid the liver and kidney toxicities of currently available pain medicines.
Lead Program SRP-001 avoids liver toxicity of acetaminophen.
SRP-001 is currently in a Phase 1 clinical trial evaluating safety, tolerability, and pharmacokinetics.
News and Milestones
OUR MISSION TO ADVANCE THE SAFE TREATMENT OF PAIN
Characterizing and carefully modeling the body’s metabolic pathways facilitated development of a novel molecule designed to avoid limitations of current non-opioid analgesics.
Our pipeline contains compounds designed to effectively treat pain and fever across a range of clinical indications, clinical settings, and dose forms.
Patients and the healthcare systems that care for them need an alternative to addictive or potentially toxic pain medications and the heavy downstream costs they incur.